https://www.selleckchem.com/pr....oducts/Dihydroartemi
In this communication we would like to share our experience in managing TORS patients during COVID-19 pandemia.The outbreak of severe acute respiratory syndrome‐related coronavirus 2 (SARS‐CoV‐2) started in Wuhan China, has become a global health concern. At present, glucocorticoid therapy is one of the most typically controversial treatments with COVID‐19 patients. Here, we reported an asymptomatic COVID‐19 patient with persistent positive detection of SARS‐CoV‐2 for 3 weeks and proposed that glucocorticoid therapy dela
Like
Comment
Share
